Non-Hodgkin Lymphoma Clinical Trial
Official title:
Prospective Observational Study of Diet, Physical Activity and Body Composition Changes During R-CHOP Treatment for NHL
In this pilot study, observational data will be collected to describe the usual trajectory of changes in dietary intake, ability to be physically active, body composition, environmental exposures, and the gut microbiome over the course of R-CHOP treatment for non-Hodgkin lymphoma (NHL).
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the
"gold standard" first-line treatment for patients with non-Hodgkin lymphoma, yet it is
estimated that R-CHOP is not curative for 30- 50% of patients. Preliminary studies suggests
that modifiable lifestyle factors such as body composition, exposure to endocrine disrupting
chemicals, and changes in the gut microbiome may contribute to variation in R-CHOP treatment
response. If true, it could be possible to modify these factors in an effort to improve
treatment outcomes, however more detailed information is needed to confirm these preliminary
findings and test whether lifestyle modification can improve outcomes.
In this observational study, data will be collected on dietary intake, ability to be
physically active, body composition, environmental exposure to endocrine disrupting chemicals
and changes in the gut microbiome over the course of R-CHOP for NHL. The study will provide
more detailed information on the usual trajectory of these lifestyle factors during R-CHOP
treatment than has previously been collected, especially how these factors co-vary over time.
The study findings are expected to inform future intervention studies aimed at improving
R-CHOP treatment outcomes.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03755414 -
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 1 | |
| Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
| Active, not recruiting |
NCT04082936 -
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01527045 -
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
|
Phase 2 | |
| Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
| Recruiting |
NCT06018129 -
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02543879 -
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT01939327 -
Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Completed |
NCT00503451 -
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01010295 -
A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae
|
Phase 2 | |
| Terminated |
NCT00383097 -
Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Completed |
NCT00509379 -
Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma
|
Phase 2 | |
| Completed |
NCT00992446 -
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05066958 -
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05205512 -
Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial
|
N/A | |
| Recruiting |
NCT05006716 -
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
| Completed |
NCT02767388 -
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
|
||
| Active, not recruiting |
NCT03997968 -
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
|
Phase 1/Phase 2 |